Current Report Filing (8-k)
07 September 2022 - 6:23AM
Edgar (US Regulatory)
0000704562
false
0000704562
2022-09-06
2022-09-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): September 6,
2022
AVID
BIOSERVICES, INC.
(Exact name of registrant as specified
in its charter)
| Delaware |
001-32839 |
95-3698422 |
(State of other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
14191
Myford Road, Tustin, California 92780
(Address of Principal Executive Offices)
Registrant’s telephone number,
including area code: (714) 508-6100
__________________________________
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ☐ | Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each Class |
Trading Symbol |
Name of each exchange on which registered |
| Common Stock, $0.001 par value
per share |
CDMO |
The NASDAQ Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐ Emerging growth company
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 2.02 |
RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
On September 6, 2022, Avid
Bioservices, Inc. (the “Company”) issued a press release to report the Company’s financial results for the first quarter
ended July 31, 2022. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. No additional information
is included in this Current Report on Form 8-K.
The information included in
this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes of, nor shall it be
deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly
set forth by specific reference in such a filing.
| ITEM 7.01 | REGULATION FD DISCLOSURE |
On September 6, 2022, at 4:30
p.m. EDT/1:30 p.m. PDT, the Company will host a conference call to discuss its first quarter ended July 31, 2022 financial results. The
webcast of the conference call will be archived on the Company’s website for approximately 30 days.
| Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits. The following material
is filed as an exhibit to this Current Report on Form 8-K:
Exhibit
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
AVID BIOSERVICES, INC. |
| |
|
|
| |
|
|
| Date: September 6, 2022 |
By: |
/s/ Daniel R. Hart |
| |
|
Daniel R. Hart |
| |
|
Chief Financial Officer |
EXHIBIT INDEX
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
From Apr 2023 to Apr 2024
